What is a UA NSTEMI?

March 10, 2020 Off By idswater

What is a UA NSTEMI?

UA/NSTEMI is characterized by an imbalance between myocardial oxygen supply and demand. Most often, the syndrome develops because of decreased myocardial perfusion resulting from coronary narrowing caused by nonocclusive thrombus formation subsequent to disruption of an atherosclerotic plaque.

How long can a NSTEMI last?

The “typical” presentation of NSTEMI is a pressure-like substernal pain, occurring at rest or with minimal exertion. The pain generally lasts more than 10 minutes and may radiate to either arm, the neck, or the jaw.

What is the difference between NSTEMI and unstable angina?

During non-STEMI, there will be elevation of the cardiac enzymes, indicative of myocardial necrosis. During unstable angina, however, there is no — or only very minimal — elevation. This is the main distinguishing feature between the two diagnoses.

What is NSTEMI diagnosis?

An NSTEMI is diagnosed when your EKG does not show the type of abnormality seen in a STEMI but your blood tests show that your heart is stressed. Unstable angina. This is the least severe type of ACS. It can be caused when a blood clot blocks a coronary artery partially or totally.

What causes an NSTEMI?

The etiology of NSTEMI varies as there are several potential causes. These include tobacco abuse, lack of physical activity, high blood pressure, high cholesterol, diabetes, obesity, and family history.

What are the treatment goals for UA / NSTEMI?

The standard treatment goals for patients with UA/NSTEMI involve the elimination of ischemia and the prevention of adverse events (death, recurrent ischemia, or myocardial infarction [MI]). The cornerstone of short- and long-term treatment in all cases is medical therapy with antiplatelet and anticoagulant medications.

Which is the best antiplatelet for UA / NSTEMI?

Aspirin and antiplatelet agents. In the absence of contraindications, aspirin is currently recommended for all patients presenting with ACS. 1 Clopidogrel, the most widely used oral P2Y12 inhibitor, is currently recommended for patients with UA/NSTEMI. Other oral P2Y12 inhibitors include prasugrel and ticagrelor.

When to use clopidogrel in patients with UA / NSTEMI?

The updated ACC/AHA guideline considers the use of clopidogrel in addition to aspirin to have a class I indication in patients with UA/NSTEMI who are undergoing an early noninterventional or interventional approach and are not at high risk for bleeding.

When was the UA / NSTEMI guideline first published?

This guideline, which was published in 2000 and updated in 2002, highlights recent medical advances and is a practical tool to help physicians provide medical care for patients with UA/NSTEMI.